STSTN GUIDELINE FOR THE PERI-OPERATIVE MANAGEMENT OF SICKLE CELL DISEASE IN ADULTS

**Document Detail**

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Clinical Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document name</td>
<td>STSTN GUIDELINE FOR THE PERI-OPERATIVE MANAGEMENT OF SICKLE CELL DISEASE IN ADULTS</td>
</tr>
<tr>
<td>Version</td>
<td>V1</td>
</tr>
<tr>
<td>Effective from</td>
<td>13th July 2020</td>
</tr>
<tr>
<td>Review date</td>
<td>13th July 2023</td>
</tr>
<tr>
<td>Authors</td>
<td>STSTN adult guideline writing group</td>
</tr>
<tr>
<td>Superseded documents</td>
<td></td>
</tr>
<tr>
<td>Keywords</td>
<td>Sickle cell disease</td>
</tr>
</tbody>
</table>

**Change History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Change details, since approved</th>
<th>Approved by</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
Elective and emergency surgery is associated with significant increased risk for patients with sickle cell disease. The following guideline addresses the risks and pre-emptive management of sickle cell patients undergoing surgery.

The following key areas need to be addressed:

- **Pre-operative planning**

  Patients should be managed jointly between haematology, surgery and anaesthetics, with close peri-operative liaison. The Haematology team should be informed as far in advance of elective surgery as possible.

  - **Emergency Surgery**
    For emergency surgery, there will not always be time for top-up or exchange transfuse pre-operatively. Patients will often need to go to critical care. *Emergency exchange transfusion should be considered for all sickle cell disease patients on critical care wards or who have undergone major emergency surgery without prior exchange transfusion.*

  - **Elective Surgery**
    Most elective surgery should be carried out in a specialist centre. Patients who do not attend a specialist centre should be referred to a specialist haemoglobinopathy team centre, as well as to the relevant surgical team in the specialist centre, processes which will take at least eight weeks prior to the elective surgery.
    A clear and expeditious referral pathway should be in place for patients being referred from local units to specialist haemoglobinopathy centres for their surgery.

  Early referral to the surgical and haematology teams in a specialist haemoglobinopathy centre (SHC) is recommended. This will allow review by both specialties in the SHC in advance of the proposed surgery and ensure that a perioperative transfusion plan, where required, can be agreed and arranged.

  As soon as the surgical team make a decision to proceed with an operation the Sickle cell team should be informed to review the patient and agree a pre-op transfusion plan. The pre-op assessment team should also inform the sickle cell team once the patient has been assessed to confirm the Sickle Cell pre-operative transfusion plan.

**STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
A written individual management plan should be in place prior to surgery, which takes into account the patient’s risk factors and the type of procedure planned. This plan should be accessible to or circulated to all relevant individuals prior to an elective surgical procedure.

The patient should be informed and involved in their management plan, and should be provided with a copy of their individual sickle peri-operative management plan.

Patients may have a history of chronic pain and be relatively insensitive to opiate analgesia. Their previous analgesia history and care plan should be taken into account when prescribing in the post-operative period. Consider referral to the acute pain team for patients who are taking regular opioids at home or where difficulties with pain relief are anticipated.

In general, day case surgery is usually not suitable for this patient group, except for eye, dental surgery, and surgery under local anaesthetic. Patients will usually require admission overnight post-operatively, for observation in most cases. If a high dependency or Intensive care unit admission is anticipated, necessary arrangements should be made in advance by the surgical team.

Sickle patients should be placed near the beginning of the theatre list to minimise time fasting and reduce likelihood of cancellation if possible, particularly when patients have had a pre-operative blood transfusion. It is acknowledged that this will not be possible in certain circumstances such as patients with a history of MRSA or VRE infection or colonisation.

**Blood Transfusion Guidance**

- **Transfusion prior to elective surgery**
  - Patients undergoing major surgery and those with a history of previous sickle related complications are at higher risk in the peri-operative period. Transfusion decisions should be made after considering patient risk factors and the nature of the planned surgery.

- **1. Low Risk**
  - Even low risk patients undergoing minor procedures under general anaesthetic with a low risk of complications require discussion with Haematology. Top up transfusion should be considered, aiming for pre-operative Hb of 100 g/l for HbSS and HbSβ0 patients.

- **2. Intermediate Risk**
  - Patients with a previous history of chest crisis (or other co-morbidity) undergoing low risk surgery; or patients undergoing Intermediate risk surgery (e.g. tonsillectomy, splenectomy, cholecystectomy or joint surgery other than total hip replacement) with no additional patient risk factors.
  - Top-up transfusion aiming for Hb of 100 g/l (irrespective of HbS %)

**STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
• **3. High Risk**
  - High-risk surgical procedures (e.g. cardiothoracic, major upper abdominal surgery, neurosurgery, total hip replacement) or previous serious sickle related complications (e.g. severe chest crisis, CVA, ITU admissions), irrespective of surgical risk.
  - Red cell exchange transfusion (preferably automated) aiming for pre-operation HbS % of <10-30%

- In patients with a high baseline Hb >95g/dl, avoid top up transfusion to prevent hyperviscosity. Particular care is needed in patients with HbSC disease as they are more likely to develop hyperviscosity related complications with top-up transfusion. Exchange transfusion is likely to be needed for all but low-risk procedures.
- Blood should be sickle negative and matched for Rh and Kell antigens and be negative for any known red cell allo-antibodies, as a minimum.
- These principles are also applicable to patients undergoing emergency surgery if time permits. As a minimum these patients should have suitable cross-matched blood available in case an emergency exchange procedure is needed. Haematology team and Blood Transfusion laboratory should be informed on admission if surgery is likely.

- Patients may have red cell alloantibodies which can delay issue of appropriate cross matched red cells for transfusion.

<table>
<thead>
<tr>
<th>High risk (cardiac risk &gt;5%)</th>
<th>Intermediate risk (cardiac risk 1–5%)</th>
<th>Low risk (cardiac risk &lt;1%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open aortic surgery</td>
<td>Elective abdominal surgery e.g. laparoscopic cholecystectomy</td>
<td>Dental</td>
</tr>
<tr>
<td>Major vascular surgery</td>
<td>Carotid endarterectomy</td>
<td>Ophthalmic</td>
</tr>
<tr>
<td>Peripheral vascular</td>
<td>Endovascular aneurysm</td>
<td>Incision and drainage of an abscess</td>
</tr>
<tr>
<td>Urgent body cavity</td>
<td>Head and neck surgery</td>
<td>Medical termination of pregnancy</td>
</tr>
<tr>
<td>Total hip replacement (THR)</td>
<td>Major Gynaecological - hysterectomy</td>
<td>Minor Gynaecological – e.g. hysteroscopy, dilatation and curettage, ERPC</td>
</tr>
<tr>
<td>Major neurosurgery</td>
<td>Major reconstructive surgery</td>
<td>Leg ulcer debridement</td>
</tr>
<tr>
<td>Joint surgery (excluding THR)</td>
<td>Minor orthopaedic procedures e.g. core decompression</td>
<td></td>
</tr>
<tr>
<td>Major urological surgery</td>
<td>Minor urology e.g. cystoscopy</td>
<td></td>
</tr>
<tr>
<td>Elective pulmonary surgery e.g. pneumonectomy</td>
<td>Bronchoscopy/EBUS</td>
<td></td>
</tr>
<tr>
<td>Mastectomy</td>
<td>Breast mass biopsy/Lumpectomy</td>
<td></td>
</tr>
</tbody>
</table>

**STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
• Patients who cannot be transfused (patient choice or rare blood type)
  Rarely, treatment with Hydroxycarbamide with or without erythropoietin, under the advice of Haematology, may be considered to improve the haemoglobin pre-operatively usually if:
  - Difficulties in transfusion are anticipated e.g. a history of repeated delayed haemolytic transfusion reaction despite steroid and IVlg cover, rare blood type due to red cell antibodies such as anti-U.
  - Patients who have had a DHTR despite steroid and IVlg therapy should be referred to the regional MDT pre-operatively and considered for Rituximab pre-treatment or any other available therapies.
  - Patient declines the use of blood products (e.g. Jehovah’s Witnesses).

For patients who are declining the use of blood products in advance of an operation, a clear advance directive stating clearly which products the patient is declining and any potentially useful product that the patient will accept must be documented and accessible/shared with the anaesthetic, surgical and sickle team.

• Pre and peri-operative management

1. Pain relief
   The patient’s usual opiate requirement should be taken into consideration, when managing post-operative pain. Their individual care/analgesia plan should be reviewed and updated prior to admission for surgery. Referral to the acute pain team may be necessary in patients with a high baseline opiate requirement. Pain management in the post-operative period should be led by the anaesthetic and acute pain teams with input from the sickle teams. Where a pre-operative analgesia plan is agreed this should be instituted. Sickle patients with a history of chronic pain may be relatively opiate resistant and require higher doses for adequate analgesia. There is a high incidence of painful crises in the post-operative period.

2. Hydration/fluid balance
   Maintain optimum hydration and start IV fluids when oral fluids are stopped. Consider admission the evening before surgery for overnight hydration in patients who are unable to drink up to two hours before surgery, continue IV fluids until the patient is able to take fluids freely. Careful attention needs to be paid to fluid balance.

3. Oxygenation
   Avoidance of hypoxia is vital to prevent sickling and tissue ischemia. Document baseline oxygen saturation (possible pre-existing cardio-respiratory disease) and ensure careful oxygenation from pre-medication, throughout the operation, until fully awake. In the immediate post-operative period patients should be closely monitored, with at least hourly observation for the first 6 hours. Any desaturation to oxygen saturations <94% (depending on usual base-line oxygenation) should be reported to medical staff and corrected with supplementary oxygen. Please escalate to the haematologist and the anaesthetist in the STSTN Clinical Guidelines Writing Group

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
immediate peri-op period. Escalate urgently if increasing oxygen requirements to maintain saturations >95% or failure to attain this despite oxygen therapy. Consider use of an incentive spirometer in sickle patients post operatively and encourage early mobilisation with physiotherapy input if appropriate.

4. Temperature Regulation
Hypothermia can trigger peripheral stasis and sickling. Keep the patient normothermic during surgery, using warm air blankets and adjust the ambient temperature in theatre as necessary. Ensure anaesthetic team is aware of these requirements in advance.

5. Prophylactic antibiotics and Infection management
Choice and duration of prophylactic antibiotics will depend on the nature of the surgery undertaken. Additional antibiotic prophylaxis should be detailed in the patient’s perioperative management plan. Patients should recommence their routine prophylaxis with Penicillin V 250mg bd (or erythromycin 250mg bd in penicillin allergic individuals) once the surgery specific antibiotic course is completed. Sickle patients are functionally hyposplenic and are at increased risk of perioperative infections, if a patient develops a fever (>38.0°C) ensure blood cultures are taken and start intravenous antibiotics as per local antimicrobial policy (NB hyposplenic and regular penicillin V exposure as prophylaxis). Check cannula and line sites daily for signs of infection and monitor for symptoms such as productive cough, shivering or myalgia. Elective surgery should not proceed in the presence of active infection as this will increase the risk of serious sickle related complications.

6. Thromboprophylaxis
Sickle cell patients are at increased risk of venous thromboembolism. Thromboprophylaxis should be considered for all procedures, particularly for major surgery or if patient will be immobile for >24 hours post procedure. Pharmaceutical thromboprophylaxis (e.g. enoxaparin 40 mg od) should be considered unless contra-indicated. See adjustments for extremes of weight and abnormal renal function as per Trust LMWH and Unfractionated Heparin Dosing and Administration Guidelines, and follow guidelines for extended thromboprophylaxis as per surgery type.

7. Tourniquets are contraindicated in patients with Sickle Cell disease.


9. Admission general points
   - Ensure the Sickle Cell team is made aware of the admission for surgery as soon as possible. In addition to FBC, HbS% or HbS+C% and routine bloods, a sample for Group and Save, antibody screening (and red cell phenotyping only if not performed previously) should be sent on admission.

STSTN Clinical Guidelines Writing Group

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
Emergency surgical procedures in patients with sickle cell disease should always be discussed immediately with the duty Haematology ST3+ or Consultant, as a peri-operative or immediately post-operative top up or exchange transfusion is likely to be required.

- Do not transfuse sickle patients without prior discussion with the Haematology/sickle cell team, unless lifesaving.
- Admit on the day before surgery if possible.
- All post-operative sickle cell inpatients should be seen regularly by the Sickle Team.
- If the post-operative sickle cell patient develops new symptoms suggestive of a sickle related complication, such as a painful crisis, chest crisis or CVA, the sickle team should be informed immediately.

**Individual Sickle Peri-Operative Management Plan**

<table>
<thead>
<tr>
<th>Personal Details:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surname: Hospital No.:</td>
</tr>
<tr>
<td>Forenames: Sex:</td>
</tr>
<tr>
<td>D.O.B.: NHS No.:</td>
</tr>
<tr>
<td>Usual specialist/local specialist haemoglobinopathy centre:</td>
</tr>
<tr>
<td>Haematology Consultant:</td>
</tr>
<tr>
<td>Surgical consultant:</td>
</tr>
</tbody>
</table>

**Clinical Details:**

- **Sickle Genotype:** HbSS / HbSβ⁺ / HbSC / HbSβ⁺ / other
- Planned surgery: ____________________________
- Operation date: ____________________________
- Red cell alloantibody: none/red cell alloantibody present (details) ____________________________
- Check with blood bank whether difficulties with blood provision: YES/NO
- History of haemolytic transfusion reaction: YES/NO
- History of acute chest syndrome or complication requiring emergency exchange transfusion or ITU admission: YES/NO
- Other medical co-morbidities: ____________________________
- Echocardiogram required: YES/NO
- HDU/ICU admission anticipated? YES/NO If YES, surgical team to book bed

**Blood transfusion:**

- For peri-operative transfusion?: Yes/No
- Automated red cell exchange/Top up (delete)
- Venous access for exchange (delete): transfusion: peripheral / portacath / femoral line
- Date of planned pre-operative transfusion: ____________________________ Location: ____________________________
- Does patient refuse blood products? YES/NO
- Has a blood product refusal proforma been completed? YES/NO

---

**STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
Steady State Values:
- Hb (g/dl):
- Platelets:
- O₂ on air (%):
- BP:
- Creatinine:
- Bilirubin:
- ALT:
- Weight:

**Analgesia Care Plan:**

*Inpatient:*
- e.g. Morphine Sulphate 10mg-20mg s/c 2-4 hourly or oxycodone 5-10mg s/c 2-4 hourly

*Outpatient:*
- e.g. Co-codamol 30/500 2 tablets qds PRN po
  - Ibuprofen 400mg tds PRN po
  - Paracetamol 1 prn qds PRN po

**Allergies:**
- e.g. Folic Acid 5mg od, Penicillin V 250mg bd

**Other Medication:**
- e.g.

**Anticoagulant and antiplatelet agents (detail):**
- Is patient on warfarin/rivaroxaban/apixaban/dabigatran/ agent/aspirin/clopidogrel/ other anticoagulant or antiplatelet? (delete as applicable and give details):
- Has an anticoagulation bridging plan been completed? YES/NO
- Omit warfarin for 5 days prior to invasive procedures, including femoral access for red cell exchange

**Date completed:**
- **Completed by:**
- **Signature:**

---

**STSTN Clinical Guidelines Writing Group**

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.
Guidelines written by the STSTN adult writing group:

Dr Sara Stuart Smith
Dr Tullie Yeghen
Dr Rachel Kesse-Adu

Contact details:

KCH adult sickle CNS: 02032994968 or 07890252387
KCH adult sickle consultants: moji.awogbade@nhs.net sara.stuartsmith@nhs.net
GSTT adult sickle CNS: 02071882710 or 07770683947 or 07770378851
GST adult sickle consultants: Jo.Howard@gstt.nhs.uk rkesse-adu@nhs.net, kate.Gardner1@gstt.nhs.uk
QE sickle sickle CNS: 07880006602
QE sickle consultants: e.douvali@nhs.net
UHL sickle CNS: 07880006629
UHL/QE sickle consultants: Tullie.Yeghen@nhs.net
CUH adult sickle CNS: 07464527317
CUH adult sickle consultants: stellakotsiopoulou@nhs.net

Additional contacts can be found on the STSTN website (www.ststn.co.uk)

STSTN Clinical Guidelines Writing Group

DISCLAIMER: This guideline is for information purposes only and is not intended to inform any individual clinical decisions. STSTN and its members do not accept any responsibility for outcome of clinical decisions made as a result of reading these guidelines. All guidelines have been peer-reviewed and agreed to be published by the relevant lead consultants in the network.